SELECT PUBLICATIONS

Abu-Khalaf MM et al. Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer. Breast Cancer Res Treat 2006;[Epub ahead of print]. Abstract

Bast A et al. Protectors against doxorubicin-induced cardiotoxicity: Flavonoids. Cell Biol Toxicol 2006;[Epub ahead of print]. Abstract

Dang C et al. Preliminary cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/ neu overexpressed/amplified breast cancer (BCA). Poster. San Antonio Breast Cancer Symposium 2005;Abstract 2041.

Elkin EB et al. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: Assessing outcome in a population-based, observational cohort. J Clin Oncol 2006;24(18):2757-64. Abstract

Giordano SH et al. Congestive heart failure (CHF) in older women treated with anthracycline (A) chemotherapy (C). Presentation. Proc ASCO 2006a;Abstract 521.

Giordano SH et al. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 2006b;24(18):2750-6. Abstract

Gradishar WJ, Kaklamani VG. Adjuvant therapy of breast cancer in the elderly: Does one size fit all? JAMA 2005;293(9):1118-20. No abstract available

Jensen BV. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Semin Oncol 2006;33(3 Suppl 8):15-21. Abstract

Jones RL et al. Anthracycline cardiotoxicity. Expert Opin Drug Saf 2006;5(6):791-809. Abstract

Jones SE et al. Final analysis: TC (docetaxel/cyclophosphamide, 4 cycles) has a superior disease-free survival compared to standard AC (doxorubicin/cyclophosphamide) in 1016 women with early stage breast cancer. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 40.

Muss HB et al; Cancer and Leukemia Group B. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005;293(9):1073-81. Abstract

Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract

Seidman AD. Systemic treatment of breast cancer. Two decades of progress. Oncology (Williston Park) 2006;20(9):983-90. Abstract

Shepherd LE et al. Left ventricular function following adjuvant chemotherapy for breast cancer: The NCIC CTG MA5 experience. Presentation. Proc ASCO 2006;Abstract 522.

Silliman RA, Ganz PA. Adjuvant chemotherapy use and outcomes in older women with breast cancer: What have we learned? J Clin Oncol 2006;24(18):2697-9. No abstract available

Villani F et al. Non-invasive monitoring of cardiac hemodynamic parameters in doxorubicin-treated patients: Comparison with echocardiography. Anticancer Res 2006;26(1B):797-801. Abstract

Youssef G, Links M. The prevention and management of cardiovascular complications of chemotherapy in patients with cancer. Am J Cardiovasc Drugs 2005;5(4):233-43. Abstract